Related Experiment Video
Updated: Apr 17, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Development of biodegradable nanocarriers loaded with a monoclonal antibody
Andrew Gdowski1,2, Amalendu Ranjan3,4, Anindita Mukerjee5,6
1Department of Molecular and Medical Genetics, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA. andrewgdowski@gmail.com.
Abstract:
Treatments utilizing monoclonal antibody therapeutics against intracellular protein-protein interactions in cancer cells have been hampered by several factors, including poor intracellular uptake and rapid lysosomal degradation. Our current work examines the feasibility of encapsulating monoclonal antibodies within poly(lactic-co-glycolic acid) (PLGA) nanoparticles using a water/oil/water double emulsion solvent evaporation technique. This method can be used to prepare protective polymeric nanoparticles for transporting functional antibodies to the cytoplasmic compartment of cancer cells. Nanoparticles were formulated and then characterized using a number of physical and biological parameters. The average nanoparticle size ranged from 221 to 252 nm with a low polydispersity index. Encapsulation efficiency of 16%-22% and antibody loading of 0.3%-1.12% were observed. The antibody molecules were released from the nanoparticles in a sustained manner and upon release maintained functionality. Our studies achieved successful formulation of antibody loaded polymeric nanoparticles, thus indicating that a PLGA-based antibody nanoformulation is a promising intracellular delivery vehicle for a large number of new intracellular antibody targets in cancer cells.
Insights
Poly(lactic-co-glycolic acid) (PLGA) nanoparticles successfully encapsulate monoclonal antibodies for cancer therapy. This novel nanoformulation enhances intracellular delivery and antibody functionality, offering a promising approach for targeting intracellular cancer proteins.
Area of Science:
- Biotechnology
- Nanomedicine
- Cancer Therapeutics
Background:
- Monoclonal antibody therapies targeting intracellular cancer proteins face challenges with cellular uptake and degradation.
- Effective delivery of antibodies into cancer cells is crucial for novel therapeutic strategies.
Purpose of the Study:
- To investigate the feasibility of encapsulating monoclonal antibodies into poly(lactic-co-glycolic acid) (PLGA) nanoparticles.
- To develop a PLGA-based nanoformulation for efficient intracellular delivery of functional antibodies to cancer cells.
Main Methods:
- Utilized a water/oil/water double emulsion solvent evaporation technique for nanoparticle preparation.
- Characterized nanoparticles for size, polydispersity index, encapsulation efficiency, and antibody loading.
- Assessed sustained release and functionality of encapsulated antibodies.
Main Results:
- Formulated nanoparticles with an average size of 221–252 nm and low polydispersity.
- Achieved encapsulation efficiencies of 16%–22% and antibody loading of 0.3%–1.12%.
- Demonstrated sustained release of functional antibodies from the PLGA nanoparticles.
Conclusions:
- Successfully formulated antibody-loaded PLGA nanoparticles as a viable intracellular delivery system.
- PLGA-based nanoformulations show promise for delivering antibodies to intracellular targets in cancer cells.
- This approach supports the development of new therapies for intracellular protein-protein interactions in cancer.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
01:24Modified-Release Drug Delivery Systems: Site-Targeted